Clinical Trial Detail

NCT ID NCT03955471
Title Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Tesaro, Inc.
Indications

ovarian clear cell carcinoma

ovarian serous carcinoma

endometrioid ovary carcinoma

fallopian tube cancer

peritoneum cancer

Therapies

Dostarlimab + Niraparib

Age Groups: adult senior

No variant requirements are available.